Propofol-Based Palliative Sedation to Treat Antipsychotic-Resistant Agitated Delirium

J Pain Palliat Care Pharmacother. 2017 Sep-Dec;31(3-4):190-194. doi: 10.1080/15360288.2017.1315476. Epub 2017 May 16.

Abstract

Delirium is a common problem in terminally ill patients that is associated with significant distress and, hence, considered a palliative care emergency. The three subtypes of delirium are hyperactive, hypoactive, and mixed, depending on the level of psychomotor activity and arousal disturbance. When agitated delirium becomes refractory in the setting of imminent dying, the agitation may be so severe that palliative sedation (PS) is required. Palliative sedation involves the administration of sedative medications with the purpose of reducing level of consciousness for patients with refractory suffering in the setting of a terminal illness. Propofol is a sedative that has a short duration of action and a very rapid onset. These characteristics make it relatively easy to titrate. Reported doses range from 50 to 70 mg per hour. The authors present a case of antipsychotic-resistant agitated delirium treated with a propofol intravenous infusion.

Keywords: antipsychotic-resistant; delirium; end of life; palliative care; palliative sedation; propofol.

Publication types

  • Case Reports

MeSH terms

  • Antipsychotic Agents
  • Delirium / complications*
  • Delirium / drug therapy*
  • Drug Resistance* / drug effects
  • Humans
  • Hypnotics and Sedatives / therapeutic use*
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Palliative Care / methods*
  • Propofol / administration & dosage
  • Propofol / therapeutic use*
  • Psychomotor Agitation / complications*
  • Psychomotor Agitation / drug therapy*

Substances

  • Antipsychotic Agents
  • Hypnotics and Sedatives
  • Propofol